Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
51.59 USD | +0.80% | -1.47% | -17.85% |
Apr. 24 | Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating | MT |
Apr. 23 | Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.85% | 11.49B | |
-4.66% | 87.53B | |
+2.63% | 40.42B | |
-20.07% | 29.48B | |
+57.86% | 25.43B | |
-44.02% | 11.3B | |
-9.14% | 11.1B | |
+5.24% | 8.75B | |
-8.42% | 7.99B | |
+2.09% | 7.67B |
- Stock Market
- Equities
- INCY Stock
- News Incyte Corporation
- Morgan Stanley Adjusts Incyte's Price Target to $76 From $77, Keeps Equalweight Rating